Telix Pharmaceuticals Ltd. ( (AU:TLX) ) has issued an announcement.
Telix Pharmaceuticals Ltd. has announced a change in the director’s interest notice, specifically involving Dr. Christian Behrenbruch. The change involves the disposal of 46,558 Performance Share Appreciation Rights, reducing the total held by Dr. Behrenbruch. This update reflects ongoing adjustments in the company’s executive shareholding structure, which may impact stakeholder perceptions and the company’s market positioning.
More about Telix Pharmaceuticals Ltd.
Telix Pharmaceuticals Ltd. operates in the biopharmaceutical industry, focusing on the development of diagnostic and therapeutic products using molecularly targeted radiation. The company primarily targets oncology and rare diseases, aiming to provide innovative solutions for unmet medical needs.
YTD Price Performance: 14.50%
Average Trading Volume: 4,747
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $5.85B
For an in-depth examination of TLX stock, go to TipRanks’ Stock Analysis page.